AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28347877 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam 0.25mg (GABAA agonist)
Number of subjects: 0
Study 28347877 — intervention group
Group type: COMPARATOR
Intervention: Placebo pill
Number of subjects: 0
Study 28347877 — intervention group
Group type: COMPARATOR
Intervention: No reminder
Number of subjects: 0
Study 25192849 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgical bilateral decompression via unilateral approach
Number of subjects: 73
Study 25192849 — intervention group
Group type: COMPARATOR
Intervention: Single-level LSS surgery
Number of subjects: 73
Study 23312808 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone and chlorambucil (6 months)
Number of subjects: 108
Study 23312808 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin (12 months)
Number of subjects: 108
Study 23312808 — intervention group
Group type: COMPARATOR
Intervention: Supportive treatment only
Number of subjects: 108
Study 23312808 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone and chlorambucil
Number of subjects: 108
Study 21476152 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily tenofovir DF plus emtricitabine (Truvada, TVD) with efavirenz (EFZ)
Number of subjects: 234
Study 21476152 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine plus lamivudine (Combivir, CBV) with efavirenz (EFZ)
Number of subjects: 234
Study 18708148 — intervention group
Group type: EXPERIMENTAL
Intervention: Methamphetamine
Number of subjects: 0
Study 18708148 — intervention group
Group type: COMPARATOR
Intervention: Cocaine
Number of subjects: 0
Study 16517193 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline 75 mg/day
Number of subjects: 156
Study 16517193 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion 300 mg/day
Number of subjects: 156
Study 16517193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 16517193 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline vs Bupropion
Number of subjects: 156
Study 12652489 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct stenting
Number of subjects: 151
Study 12652489 — intervention group
Group type: COMPARATOR
Intervention: Conventional stenting
Number of subjects: 151
Study 11086783 — intervention group
Group type: EXPERIMENTAL
Intervention: Blind manual method for positioning double-lumen tube (DLT)
Number of subjects: 58
Study 11086783 — intervention group
Group type: COMPARATOR
Intervention: Conventional method using fiberoptic bronchoscope (FOB)
Number of subjects: 58
Study 8826548 — intervention group
Group type: EXPERIMENTAL
Intervention: PTF 400 mg bid
Number of subjects: 25
Study 8826548 — intervention group
Group type: EXPERIMENTAL
Intervention: PTF 400 mg tid
Number of subjects: 25
Study 8826548 — intervention group
Group type: EXPERIMENTAL
Intervention: PTF 400 mg bid or tid
Number of subjects: 25
Study 1417051 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipseudomonal treatment at intervals of four months until serum IgG titre returned to control range
Number of subjects: 19
Study 1417051 — intervention group
Group type: COMPARATOR
Intervention: Observation (no antipseudomonal treatment)
Number of subjects: 19
Study 3880879 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone therapy
Number of subjects: 0
Study 3880879 — intervention group
Group type: COMPARATOR
Intervention: Control (no dexamethasone)
Number of subjects: 0
Study 29534125 — intervention group
Group type: EXPERIMENTAL
Intervention: MicroSaw
Number of subjects: 53
Study 29534125 — intervention group
Group type: COMPARATOR
Intervention: Piezosurgery
Number of subjects: 53
Study 29534125 — intervention group
Group type: EXPERIMENTAL
Intervention: MicroSaw and Piezosurgery
Number of subjects: 53
Study 26509236 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined physical exercise and psychosocial intervention
Number of subjects: 68
Study 26509236 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 68
Study 26158769 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise
Number of subjects: 222
Study 26158769 — intervention group
Group type: COMPARATOR
Intervention: Control (usual exercise)
Number of subjects: 222
Study 24016454 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 18113
Study 24016454 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18113
Study 20950304 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil for the treatment of mild ED
Number of subjects: 176
Study 20950304 — intervention group
Group type: COMPARATOR
Intervention: General ED clinical trial population
Number of subjects: 176
Study 18296978 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic cardioacceleration before each set of resistance exercises
Number of subjects: 48
Study 18296978 — intervention group
Group type: COMPARATOR
Intervention: Rest (control group)
Number of subjects: 48
Study 16571739 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral flickering stimuli presented continuously over entire trial blocks with subjects counting target letter 'X' in the cued hemifield.
Number of subjects: 0
Study 15110129 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide
Number of subjects: 885
Study 15110129 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 885
Study 11096333 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate (6 tablets of 333 mg per day)
Number of subjects: 12
Study 11096333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9129859 — intervention group
Group type: EXPERIMENTAL
Intervention: Irwin's restricted mean
Number of subjects: 0
Study 9129859 — intervention group
Group type: COMPARATOR
Intervention: Logrank test
Number of subjects: 0
Study 9129859 — intervention group
Group type: COMPARATOR
Intervention: Censored data generalization of the Wilcoxon test
Number of subjects: 0
Study 8171300 — intervention group
Group type: EXPERIMENTAL
Intervention: Various interventions used in treatment trials
Number of subjects: 7
Study 8171300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 3524696 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychopharmacological treatment
Number of subjects: 36
Study 3524696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 29733647 — intervention group
Group type: EXPERIMENTAL
Intervention: Flocculant-disinfectant sachets in Pakistan
Number of subjects: 0
Study 29733647 — intervention group
Group type: EXPERIMENTAL
Intervention: Flocculant-disinfectant sachets in Zambia
Number of subjects: 0
Study 27809814 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary communication training program (9 hours e-learning + 20 hours on-site skills training)
Number of subjects: 137
Study 27809814 — intervention group
Group type: COMPARATOR
Intervention: Control group without training
Number of subjects: 137
Study 27809814 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary communication training program
Number of subjects: 137
Study 24833256 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 1024
Study 24833256 — intervention group
Group type: COMPARATOR
Intervention: Comparator antibiotics
Number of subjects: 1024
Study 22508435 — intervention group
Group type: EXPERIMENTAL
Intervention: Wellness Recovery Action Planning (WRAP) intervention, consisting of eight weekly 2.5-hour sessions delivered by peers in recovery from serious mental illness.
Number of subjects: 519
Study 22508435 — intervention group
Group type: EXPERIMENTAL
Intervention: Wellness Recovery Action Planning (WRAP) intervention
Number of subjects: 519
Study 22508435 — intervention group
Group type: COMPARATOR
Intervention: Services as usual (control group)
Number of subjects: 519
Study 20516308 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation program for six weeks
Number of subjects: 105
Study 20516308 — intervention group
Group type: COMPARATOR
Intervention: Control group (no smoking cessation program)
Number of subjects: 105
Study 18609709 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (LAC): lansoprazole 30 mg, amoxycillin 1 g, clarithromycin 500 mg, all b.d.
Number of subjects: 101
Study 18609709 — intervention group
Group type: COMPARATOR
Intervention: Quadruple therapy (LMBT): lansoprazole 30 mg b.d., metronidazole 500 mg t.d.s., bismuth subcitrate 240 mg b.d., tetracycline chloride 500 mg q.d.s.
Number of subjects: 101
Study 16077990 — intervention group
Group type: EXPERIMENTAL
Intervention: CDDP + 5-FU
Number of subjects: 197
Study 16077990 — intervention group
Group type: COMPARATOR
Intervention: CDDP + VP16
Number of subjects: 197
Study 11346861 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg zoledronic acid
Number of subjects: 287
Study 11346861 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg zoledronic acid
Number of subjects: 287
Study 11346861 — intervention group
Group type: COMPARATOR
Intervention: 90 mg pamidronate
Number of subjects: 287
Study 11346861 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg and 8 mg zoledronic acid
Number of subjects: 287
Study 11346861 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg zoledronic acid (retreatment)
Number of subjects: 287
Study 9212042 — intervention group
Group type: EXPERIMENTAL
Intervention: L-T4 treatment (20 microg/kg daily for 2 weeks)
Number of subjects: 40
Study 9212042 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 40
Study 7963146 — intervention group
Group type: EXPERIMENTAL
Intervention: Microparticulated protein (MPP, Simplesse) frozen dessert
Number of subjects: 24
Study 7963146 — intervention group
Group type: COMPARATOR
Intervention: Super premium ice cream (approximately 16% butterfat)
Number of subjects: 24
Study 3309757 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymostimulin for 2 weeks after the second cycle of chemotherapy
Number of subjects: 20
Study 3309757 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional immunotherapy)
Number of subjects: 20
Study 28635021 — intervention group
Group type: EXPERIMENTAL
Intervention: Objectification (body focus)
Number of subjects: 0
Study 28635021 — intervention group
Group type: EXPERIMENTAL
Intervention: Provocation (yes)
Number of subjects: 0
Study 28635021 — intervention group
Group type: COMPARATOR
Intervention: No objectification
Number of subjects: 0
Study 27686345 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower threshold (transfusion at 7 g/dl or less)
Number of subjects: 1005
Study 27686345 — intervention group
Group type: COMPARATOR
Intervention: Higher threshold (transfusion at 9 g/dl or less)
Number of subjects: 1005
Study 23438305 — intervention group
Group type: EXPERIMENTAL
Intervention: Islet preparations with microbial contamination (19 out of 343, 5.5%)
Number of subjects: 164
Study 23438305 — intervention group
Group type: EXPERIMENTAL
Intervention: Islet preparations with microbial contamination
Number of subjects: 164
Study 21256472 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted colorectal resection
Number of subjects: 52
Study 21256472 — intervention group
Group type: COMPARATOR
Intervention: Open colorectal resection
Number of subjects: 52
Study 21256472 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve sparing surgery (not performed)
Number of subjects: 52
Study 21256472 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal resection
Number of subjects: 52
Study 21256472 — intervention group
Group type: EXPERIMENTAL
Intervention: Parametrial resection
Number of subjects: 52
Study 19920414 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose 5% in water (D5W)
Number of subjects: 50
Study 19920414 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 50
Study 16566619 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 142
Study 14631328 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized training for 2 months
Number of subjects: 28
Study 10945310 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral coadministration of 100 mg talinolol with 0.5 mg digoxin
Number of subjects: 10
Study 10945310 — intervention group
Group type: COMPARATOR
Intervention: Coinfusion of 30 mg talinolol with oral digoxin
Number of subjects: 10
Study 10945310 — intervention group
Group type: COMPARATOR
Intervention: Digoxin alone
Number of subjects: 10
Study 9433787 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 3
Study 9433787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 8280829 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing dietary fat
Number of subjects: 0
Study 8280829 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary regimens
Number of subjects: 0
Study 8280829 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial participation
Number of subjects: 0
Study 8280829 — intervention group
Group type: EXPERIMENTAL
Intervention: Suggestions for adherence
Number of subjects: 0
Study 3224001 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening with Lipid Research Clinics Coronary Primary Prevention Trial criteria (≥ 265 mg/dL)
Number of subjects: 10068
Study 3224001 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening with National Cholesterol Education Program (NCEP) criteria (≥ 200 mg/dL)
Number of subjects: 10068
Study 3224001 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening with NIH Consensus Conference on Lipid Lowering age-related definitions
Number of subjects: 10068
Study 3224001 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up cholesterol determination for hypercholesterolemia subjects (≥ 265 mg/dL at screening)
Number of subjects: 10068
Study 29114934 — intervention group
Group type: EXPERIMENTAL
Intervention: Territorial user rights for fisheries (TURFs) system
Number of subjects: 0
Study 29114934 — intervention group
Group type: EXPERIMENTAL
Intervention: Fisher associations authorizing poaching
Number of subjects: 0
Study 29114934 — intervention group
Group type: EXPERIMENTAL
Intervention: Government support for enforcement
Number of subjects: 0
Study 28745999 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab weekly (162 mg)
Number of subjects: 251
Study 28745999 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab every other week (162 mg)
Number of subjects: 251
Study 28745999 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 26-week prednisone taper
Number of subjects: 251
Study 28745999 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 52-week prednisone taper
Number of subjects: 251
Study 28745999 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab weekly or every other week
Number of subjects: 251
Study 28745999 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab weekly
Number of subjects: 251
Study 28745999 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab every other week
Number of subjects: 251
Study 26287338 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin group (methylprednisolone + ulinastatin)
Number of subjects: 104
Study 26287338 — intervention group
Group type: COMPARATOR
Intervention: IVIG group
Number of subjects: 104
Study 23773357 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin (MCFG) administered intravenously at a dose of 3 mg/kg/day
Number of subjects: 39
Study 23773357 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole (FLCZ) administered intravenously at a dose of 5 mg/kg/day
Number of subjects: 39
Study 21969509 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral talactoferrin (1.5 g in 15 mL phosphate-based buffer) twice per day for a maximum of three 14-week cycles (12 weeks on, 2 weeks off)
Number of subjects: 100
Study 21969509 — intervention group
Group type: COMPARATOR
Intervention: Placebo (15 mL phosphate-based buffer) twice per day for a maximum of three 14-week cycles (12 weeks on, 2 weeks off)
Number of subjects: 100
Study 21969509 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral talactoferrin (1.5 g in 15 mL phosphate-based buffer)
Number of subjects: 100
Study 21969509 — intervention group
Group type: COMPARATOR
Intervention: Placebo (15 mL phosphate-based buffer)
Number of subjects: 100
Study 18171442 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial‐CERT
Number of subjects: 50
Study 18171442 — intervention group
Group type: EXPERIMENTAL
Intervention: CR‐10
Number of subjects: 50
Study 19906454 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 33 × 10(3) IU before PCI, and 24 and 48 hours after admission
Number of subjects: 30
Study 19906454 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO)
Number of subjects: 30
Study 19906454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16046344 — intervention group
Group type: EXPERIMENTAL
Intervention: Short term detraining (6 weeks)
Number of subjects: 21
Study 16046344 — intervention group
Group type: EXPERIMENTAL
Intervention: Long term detraining (52 weeks)
Number of subjects: 21
Study 16046344 — intervention group
Group type: COMPARATOR
Intervention: Exercise training (9 weeks multicomponent exercise training programme)
Number of subjects: 21
Study 12193492 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil at a 15 microg x kg(‐1) dose
Number of subjects: 20
Study 12193492 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil at a 30 microg x kg(‐1) dose
Number of subjects: 20
Study 9640850 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric evaluation and management (GEM) for six months
Number of subjects: 522
Study 9640850 — intervention group
Group type: COMPARATOR
Intervention: Usual care for six months
Number of subjects: 522
Study 9640850 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric evaluation and management (GEM)
Number of subjects: 522
Study 8021627 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative reward
Number of subjects: 0
Study 8021627 — intervention group
Group type: COMPARATOR
Intervention: Individualistic reward
Number of subjects: 0
Study 3052893 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan (2 g i.v. single dose)
Number of subjects: 460
Study 3052893 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin (2 g i.v. before surgery and after 8 hours)
Number of subjects: 460
Study 3052893 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan
Number of subjects: 460
Study 3052893 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 460
Study 30346431 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine 16 mg/day for 6 months followed by memantine 20 mg/day for responders
Number of subjects: 38
Study 30346431 — intervention group
Group type: COMPARATOR
Intervention: Galantamine 16 mg/day for 6 months
Number of subjects: 38
Study 28615375 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 43 g almonds/d
Number of subjects: 48
Study 26518022 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive group‐based intervention (52 group sessions and telephone counseling contacts)
Number of subjects: 692
Study 26518022 — intervention group
Group type: COMPARATOR
Intervention: Non‐intensive control (two in‐person counseling sessions)
Number of subjects: 692
Study 26518022 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive group‐based intervention
Number of subjects: 692
Study 26518022 — intervention group
Group type: COMPARATOR
Intervention: Non‐intensive control
Number of subjects: 692
Study 24267093 — intervention group
Group type: EXPERIMENTAL
Intervention: Menadione (MD) as a pre‐column reagent for HPLC analysis of aliphatic thiols
Number of subjects: 0
Study 24267093 — intervention group
Group type: COMPARATOR
Intervention: Standard and placebo solutions
Number of subjects: 0
Study 24267093 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC recovery studies
Number of subjects: 0
Study 24267093 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine chromatographic separations on a Synergi MAX‐RP column
Number of subjects: 0
Study 19452271 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeking Safety (SS), a cognitive behavioral intervention for women with PTSD and SUD
Number of subjects: 346
Study 19452271 — intervention group
Group type: COMPARATOR
Intervention: Women's Health Education (WHE), an attention control psychoeducational group
Number of subjects: 346
Study 17972276 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose glycine (0.8 g/kg)
Number of subjects: 0
Study 17972276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17542716 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey respondents who had heard of clinical trials (CTs)
Number of subjects: 100
Study 17542716 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey respondents who had previously been approached to participate in a trial
Number of subjects: 100
Study 17542716 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey respondents who agreed to participate in a trial
Number of subjects: 100
Study 17542716 — intervention group
Group type: EXPERIMENTAL
Intervention: General findings regarding attitudes towards clinical trials
Number of subjects: 100
Study 17542716 — intervention group
Group type: EXPERIMENTAL
Intervention: Need for education programs
Number of subjects: 100
Study 12908658 — intervention group
Group type: EXPERIMENTAL
Intervention: Second generation antipsychotics (olanzapine, quetiapine, risperidone, ziprasidone)
Number of subjects: 1500
Study 12908658 — intervention group
Group type: COMPARATOR
Intervention: Perphenazine (midpotency first generation antipsychotic)
Number of subjects: 1500
Study 12908658 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label clozapine or double-blinded second generation drug (available but not assigned in phase 1)
Number of subjects: 1500
Study 12908658 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blinded randomization to ziprasidone or another second generation drug (available but not assigned in phase 1)
Number of subjects: 1500
Study 11092778 — intervention group
Group type: EXPERIMENTAL
Intervention: One-session psychological treatment
Number of subjects: 91
Study 11092778 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral selected midazolam
Number of subjects: 91
Study 11092778 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 91
Study 8854297 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 21
Study 8854297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 1629885 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (75 mg/day)
Number of subjects: 86
Study 1629885 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg/day)
Number of subjects: 86